JP Patent

JP2018048182A — ブルトン型チロシンキナーゼ阻害剤の結晶形態

Assigned to Pharmacyclics LLC · Expires 2018-03-29 · 8y expired

What this patent protects

【課題】１−（（Ｒ）−３−（４−アミノ−３−（４−フェノキシフェニル）−１Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−１−イル）ピペリジン−１−イル）ｐｒｏｐ−２−ｅｎ−１−オンの新規な結晶形態の提供。【解決手段】５．２±０．１°２−シータ、１０．２±０．１°２−シータ、及び２０．８±０．１°２−シータでの特徴的なピークを備えた、Ｘ線粉末回折（ＸＲＰＤ）パターンを有する、結晶形態。【選択図】図１

USPTO Abstract

【課題】１−（（Ｒ）−３−（４−アミノ−３−（４−フェノキシフェニル）−１Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−１−イル）ピペリジン−１−イル）ｐｒｏｐ−２−ｅｎ−１−オンの新規な結晶形態の提供。【解決手段】５．２±０．１°２−シータ、１０．２±０．１°２−シータ、及び２０．８±０．１°２−シータでの特徴的なピークを備えた、Ｘ線粉末回折（ＸＲＰＤ）パターンを有する、結晶形態。【選択図】図１

Drugs covered by this patent

Patent Metadata

Patent number
JP2018048182A
Jurisdiction
JP
Classification
—
Expires
2018-03-29
Drug substance claim
No
Drug product claim
No
Assignee
Pharmacyclics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.